IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

in CHF 1 000

 

Notes

 

01.01.–31.03.2023

 

01.01.–31.03.2022

 

 

Operating income

 

 

 

 

 

 

 

 

Foreign exchange gains

 

 

 

644

 

720

 

 

Other income

 

 

 

5

 

3

 

 

 

 

 

 

649

 

723

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Net losses from securities

 

3

 

(243 214)

 

(288 406)

 

 

Finance expenses

 

 

 

(1 108)

 

(248)

 

 

Administrative expenses

 

6

 

(8 943)

 

(10 485)

 

 

Other expenses

 

 

 

(1 223)

 

(1 426)

 

 

 

 

 

 

(254 488)

 

(300 565)

 

 

Profit/(loss) before tax

 

7

 

(253 839)

 

(299 842)

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(16)

 

(19)

 

 

Profit/(loss) for the period

 

 

 

(253 855)

 

(299 861)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

(253 855)

 

(299 861)

 

 

 

 

 

 

 

 

 

 

 

Income per share in CHF

 

8

 

(4.63)

 

(5.43)

 

 

Diluted income per share in CHF

 

8

 

(4.63)

 

(5.43)

 

 

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer